Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Henlius Wins Chinese Approval For Rituximab RA Indication

Wider Potential Patient Population Allows Firm ‘Differentiated Strategy’

Executive Summary

Henlius says it can now pursue a “differentiated strategy” for its HLX01 rituximab biosimilar in China, after winning approval for a key rheumatoid arthritis indication from the NMPA.

You may also be interested in...



Henlius Delivers On Innovation Agenda In 2021

Henlius has focused its efforts on becoming a fully-fledged biopharmaceutical company during 2021, moving away from its roots as a biosimilar drug company.

Henlius’ Rituximab Results Bolster RA Ambitions In China

Shanghai Henlius Biotech has taken its groundbreaking Chinese rituximab biosimilar a step closer to securing a key rheumatoid arthritis indication.

Henlius Gets Green Light For Adalimumab In China

After receiving approval from the Chinese regulatory body for rituximab and trastuzumab, Shanghai Henlius Biotech has now received approval for its HLX03 adalimumab biosimilar rival to Humira. The company has partnered with Wanbang Biopharma for commercialization of HLX03 in China. 

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB151702

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel